Publications by authors named "Naveed Shams"

Claim this Profile
R
Retinal gene therapy for Stargardt disease with dual AAV intein vectors is both safe and effective in large animal models.
Rita Ferla, Eugenio Pugni, Mariangela Lupo, Paola Tiberi, Federica Fioretto, Naveed Shams

Sci Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study.
Victor H Gonzalez, Brian Berger, Roger Goldberg, Carmelina M Gordon, Rahul N Khurana, Naveed Shams

Transl Vis Sci Technol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
Kenneth W Olander, Michelle A Sato, Marc A Abrams, Gary W Jerkins, Fenghe Lu, Naveed K Shams

J Glaucoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
Masahiro Fuwa, Atsushi Shimazaki, Noriko Odani-Kawabata, Tomoko Kirihara, Takazumi Taniguchi, Naveed K Shams

J Ocul Pharmacol Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Noriko Odani-Kawabata, Naveed K Shams

Am J Ophthalmol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.
Pauline T Merrill, W Lloyd Clark, Alay S Banker, Christine Fardeau, Pablo Franco, Naveed Shams

Ophthalmology· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
Yoshihiko Esaki, Osamu Katsuta, Hitomi Kamio, Takahisa Noto, Hidetoshi Mano, Naveed K Shams

J Ocul Pharmacol Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Makoto Aihara, Auli Ropo, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Naveed Shams

Jpn J Ophthalmol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells.
Yasuko Yamamoto, Takazumi Taniguchi, Tomoaki Inazumi, Ryo Iwamura, Kenji Yoneda, Naveed K Shams

J Ocul Pharmacol Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Yuki Tanaka, Kenzo Yamamura, Naveed K Shams

J Ocul Pharmacol Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Kathy Liu, Naveed K Shams

J Glaucoma· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
Masahiro Fuwa, Carol B Toris, Shan Fan, Takazumi Taniguchi, Masaki Ichikawa, Naveed K Shams

J Ocul Pharmacol Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.
Ryo Iwamura, Masayuki Tanaka, Eiji Okanari, Tomoko Kirihara, Noriko Odani-Kawabata, Naveed Shams

J Med Chem· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
Tomoko Kirihara, Takazumi Taniguchi, Kenzo Yamamura, Ryo Iwamura, Kenji Yoneda, Naveed Shams

Invest Ophthalmol Vis Sci· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
Quan Dong Nguyen, Pauline T Merrill, W Lloyd Clark, Alay S Banker, Christine Fardeau, Naveed Shams

Ophthalmology· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study.
Quan Dong Nguyen, Mohamed A Ibrahim, Anthony Watters, Millena Bittencourt, Jithin Yohannan, Naveed Shams

J Ophthalmic Inflamm Infect· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Carl D Regillo, David M Brown, Prema Abraham, Huibin Yue, Tsontcho Ianchulev, Naveed Shams

Am J Ophthalmol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Napoleone Ferrara, Lisa Damico, Naveed Shams, Henry Lowman, Robert Kim

Retina· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of vascular endothelial growth factor in ocular angiogenesis.
Naveed Shams, Tsontcho Ianchulev

Ophthalmol Clin North Am· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Jeffrey S Heier, Andrew N Antoszyk, Peter Reed Pavan, Steven R Leff, Philip J Rosenfeld, Naveed Shams

Ophthalmology· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Philip J Rosenfeld, Jeffrey S Heier, Gary Hantsbarger, Naveed Shams

Ophthalmology· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
Philip J Rosenfeld, Steven D Schwartz, Mark S Blumenkranz, Joan W Miller, Julia A Haller, Naveed Shams

Ophthalmology· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
Jack V Greiner, Thomas Mundorf, Harvey Dubiner, John Lonsdale, Richard Casey, Naveed B K Shams

Am J Ophthalmol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
Mark B Abelson, Matthew J Chapin, Barry M Kapik, Naveed B K Shams

Arch Ophthalmol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of unoprostone isopropyl 0.15% ophthalmic solution in patients with mild to moderate asthma.
Kulasiri A Gunawardena, Nathan Crame, Beat Mertz, Naveed Shams

Ophthalmologica· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis